AN2 Therapeutics (ANTX) CMO becomes reporting insider with no listed shares

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. (ANTX) reported that Trenor Cameron C. III, its Chief Medical Officer, filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable transactions or holdings data, serving as the baseline ownership record as this officer becomes a reporting person.

Key Terms

Form 3, Chief Medical Officer, ten percent owner, reporting person

4 terms

Form 3 regulatory

"filed an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Medical Officer other

"Trenor Cameron C. III, its Chief Medical Officer, filed"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

ten percent owner regulatory

"he is not listed as a director or a ten percent owner"

reporting person regulatory

"becomes a reporting person for AN2 Therapeutics, Inc."

FAQ

What does the Form 3 filing by Trenor Cameron C. III for ANTX show?

It shows that Trenor Cameron C. III, the Chief Medical Officer of AN2 Therapeutics, Inc. (ANTX), has filed an initial Form 3 as a reporting person. The filing does not list any specific transactions or share holdings.

Were any ANTX shares bought or sold in this Form 3 filing?

No. The Form 3 for AN2 Therapeutics, Inc. (ANTX) reports no transactions. The transaction summary shows zero buys, zero sells, and no derivative exercises or gifts.

What is Trenor Cameron C. III’s role at AN2 Therapeutics, Inc. (ANTX)?

Trenor Cameron C. III is reported as an officer of AN2 Therapeutics, Inc. (ANTX) with the title Chief Medical Officer. He is not listed as a director or a ten percent owner in this filing.

Does the Form 3 indicate Trenor Cameron C. III is a ten percent owner of ANTX?

No. The filing explicitly indicates that Trenor Cameron C. III is not a ten percent owner of AN2 Therapeutics, Inc. (ANTX). He is identified solely in his capacity as Chief Medical Officer.

Are there any Rule 10b5-1 trading plans disclosed in this ANTX Form 3?

No. The filing data show the Rule 10b5-1 plan indicator as null, reflecting that this initial Form 3 does not affirm trades under a Rule 10b5-1 plan and reports no transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 02:16 PM Accepted by SEC EDGAR 08/27/2026 - 02:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Trenor Cameron C. III

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/24/2026

3. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Eric Easom, Attorney-in-Fact for Cameron Trenor	08/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)